BMSD : 10.65048
BMSD : 10.65048
https://doi.org/10.65048/ijbmr
Search
About Us
Authors
Reviewers
Editorial Board
Contact Us

Development and in-vitro characterization of mucoadhesive vaginal tablet

Authors:Nakul S. Dhore*, Dr. Nishan N. Bobade, Dr. Shrikant D. Pande, Dr. Vikrant P. Wankhade, Dr. Sandeep C. Atram, Syed Faizan
Int J Biol Med Res. 2026; 17(4): 8755-8760  |  PDF File  |  Full Text
DOI No.: 10.65048/ijbmr.2026.17.4.8755.1084

Abstract

Vaginal drug delivery has gained increasing attention due to its ability to bypass first-pass metabolism, provide localized therapy, and reduce systemic side effects. The presence of a mucosal layer necessitates the use of mucoadhesive systems to enhance residence time and drug absorption. Genital herpes, primarily caused by HSV-2, remains a significant global health concern, with high prevalence among women. Conventional oral therapy with acyclovir is limited by low bioavailability (15–30%), justifying the need for an alternative delivery approach. This study aimed to develop and optimize a mucoadhesive vaginal tablet of acyclovir capable of sustaining drug release for 8 hours using a combination of HPMC K15M and chitosan HCl. Tablets were prepared by direct compression and optimized using a 3² factorial design, evaluating the influence of polymer concentrations on swelling index, mucoadhesive strength, and drug release. FTIR and DSC studies confirmed compatibility and physicochemical stability of acyclovir with selected excipients. Swelling index ranged from 100.47% to 142.80%, increasing with polymer concentration. Mucoadhesive strength (37.8–53.1 g) and mucoadhesive time (10.20–13.40 h) showed a direct relationship with chitosan content due to its cationic interaction with mucin. Drug content was uniform across formulations (98–101%). In vitro drug release studies demonstrated sustained release up to 8 hours, with lower polymer concentrations showing faster release. Most formulations followed zero-order kinetics, indicating controlled and consistent drug release, while F1 exhibited a Korsmeyer–Peppas mechanism. In conclusion, the combination of HPMC K15M and chitosan HCl exhibited a synergistic effect, balancing mucoadhesion and sustained drug release. The optimized formulation successfully prolonged drug residence time and maintained therapeutic drug levels, offering a promising alternative for effective management of genital herpes with reduced dosing frequency.